Boehringer Ingelheim Venture Fund (BIVF), the corporate venturing affiliate of Germany-based pharmaceutical company Boehringer Ingelheim, has established a US office Cambridge, just outside Boston, USA. The fund plans to invest a total of $130m in ten life sciences start-ups, with no time limit on when to make the investments.
BIVF’s US office has been established by Martin Heidecker, who told the Boston Herald that he had already found companies he was interested in backing and that there would be investments “in the near future”: he added that he was looking for “difference-makers”.